CompletedPhase 3

A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

United States288 participantsStarted 2005-01

Plain-language summary

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with perennial allergic rhinitis (PAR).

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Diagnosis of perennial allergic rhinitis (PAR). * Must comply with study procedures and be literate. Exclusion criteria: * Significant concomitant medical conditions. * Use of corticosteroids. * Use of allergy medications and some other medications during the study. * Current tobacco use. * Clinically significant abnormal ECG or laboratory abnormality.

What they're measuring

Mean change from baseline over the entire treatment period in daily, reflective total nasal symptom scores. Subjects complete diaries twice daily (every 12 hours) reporting the severity of their PAR symptoms.

Trial details

NCT IDNCT00103454

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2005-05

View on ClinicalTrials.gov More Rhinitis, Allergic, Perennial trials